Table I.
Baseline patient and treatment characteristics
| All n = 1,988 (100) | BSA <10% n = 1,721 (86.6) | BSA ≥10% n = 267 (13.4) | |
|---|---|---|---|
| Demographic data | |||
| Age, years, mean (SD) | 39.5 (12.9) | 39.3 (12.8) | 40.8 (13.3) |
| Male, n (%) | 678 (34.1) | 587 (34.1) | 91 (34.1) |
| Diagnosis age ≤18 years, n (%) | 1,019 (51.3) | 864 (50.2) | 155 (58.1) |
| Disease duration, years, mean (SD) | 19.5 (14.2) | 19.1 (13.9) | 22.5 (15.8) |
| Flare frequency over past year | |||
| Patients with ≥1 flare in the past year, n (%) | 1,804 (94.8) | 1,576 (94.9) | 228 (94.2) |
| Mean number of flares (SD) | 7.5 (20.1) | 6.8 (17.2) | 12.3 (33.4) |
| Median number of flares (IQR) | 4 (2–6) | 4 (2–6) | 5 (3–9) |
| Current treatment used for flare management by BSA involvement, n | 1,172 | 1,049 | 123 |
| Topical onlya, n (%) | 860 (73.4) | 777 (74.1) | 83 (67.5) |
| cSysb,c, n (%) | 297 (25.3) | 258 (24.6) | 39 (31.7) |
| Biologicsc, n (%) | 15 (1.3) | 14 (1.3) | 1 (0.8) |
| Current treatment by BSA involvement, n | 1,988 | 1,721 | 267 |
| Topical corticosteroids, n (%) | 1,564 (78.7) | 1,346 (78.2) | 218 (81.6) |
| Topical calcineurin-inhibitors, n (%) | 506 (25.5) | 430 (25.0) | 76 (28.5) |
| Systemic corticosteroidsc, n (%) | 379 (19.1) | 323 (18.8) | 56 (21.0) |
| Systemic immunosuppressants (oral/injected)c, n (%) | 240 (12.1) | 194 (11.3) | 46 (17.2) |
| Biologicsc, n (%) | 46 (2.3) | 39 (2.3) | 7 (2.6) |
No missing data imputation was applied. Only observed data were used for each question.
a
Topical corticosteroids, topical calcineurin inhibitors.
b
Systemic corticosteroids, systemic immunosuppressants.
c
Systemic and biologics treatment could have been used in combination with topicals or as monotherapy.
BSA: body surface area; cSys: conventional systemic; IQR: interquartile range; SD: standard deviation.